{"id":"asmdc","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, aSMDC reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This makes it a potential treatment for diabetes. Its exact mechanism of action is still being studied in phase 3 clinical trials.","oneSentence":"aSMDC is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:41.079Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04976153","phase":"PHASE3","title":"Skeletal Muscle-derived Cell Implantation for Treatment of Fecal Incontinence","status":"RECRUITING","sponsor":"Innovacell GmbH","startDate":"2022-05-11","conditions":"Fecal Incontinence","enrollment":290}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"aSMDC","genericName":"aSMDC","companyName":"Innovacell GmbH","companyId":"innovacell-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"aSMDC is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}